Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

digital therapy

National Institute for Health and Care Excellence NICE logo

NICE recommends Astellas’ Betmiga for overactive bladder

Final draft guidance recommends Vesicare successor

Former NICE chair joins board of biotech

Sir Michael Rawlins joins board of Intra-Cellular Therapeutics

- PMLiVE

Lundbeck’s Steve Turley re-elected as EMG chair

And Actelion's Robin Bhattacherjee retains vice-chair position

- PMLiVE

Value-based pricing “not in patient interest”

Think-tank 2020health calls for rethink of UK drug pricing plans

- PMLiVE

NICE tasked with speeding NHS uptake of new technology

Expanded role will see it takeover the work of the NHS Technology Adoption Centre

Novartis building

NICE turns down Novartis’ blood cancer drug Jakavi

Uncertainties remain about drug’s cost-effectiveness, according to final draft guidance

Novartis day

Xolair gets asthma green light from NICE

Final guidance recommends Novartis drug for severe persistent asthma 

- PMLiVE

BMS wins wider NICE Orencia arthritis approval

But only after cutting the drug's price

- PMLiVE

Roche faces another NICE rejection for Avastin

Draft guidance turns down drug for use in ovarian cancer

- PMLiVE

EMA recommends heart risk restriction for Servier’s Protelos

Use of osteoporosis drug likely to be further tightened up

National Institute for Health and Care Excellence NICE logo

Cell Therapeutics fails to gain NICE backing for blood cancer drug

Watchdog says not enough evidence to show Pixuvri is more effective than current treatments

- PMLiVE

Additional NICE recommendation for Novartis’ Lucentis

Says drug can be used in patients with macular oedema caused by blockage of the veins in the retina

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links